Ontology type: schema:ScholarlyArticle Open Access: True
1992-08
AUTHORSA R Dixon, L Jackson, S Chan, J Haybittle, R W Blamey
ABSTRACTSixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m-2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in all sites, including visceral metastases and receptor negative patients. There were no significant differences between treatment groups in the median time (5 months each) to disease progression response duration or survival (13 months megesterol, 11 months mitozantrone) from commencing second-line therapy. Toxicity was considerably higher in the mitozantrone group. Second-line hormonal therapies can produce similar therapeutic results as those achieved from a short course of a 'short option' single agent cytotoxic in patients who were previously thought hormone insensitive. Provided that the patient does not have life threatening disease a trial of megesterol acetate is worth consideration in that it does not prejudice subsequent response to combination cytotoxic chemotherapy. More... »
PAGESbjc1992277
http://scigraph.springernature.com/pub.10.1038/bjc.1992.277
DOIhttp://dx.doi.org/10.1038/bjc.1992.277
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1031193368
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/1503915
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Breast Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Resistance",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Megestrol",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Megestrol Acetate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Mitoxantrone",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Staging",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Probability",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptors, Estrogen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tamoxifen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Time Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Nottingham City Hospital",
"id": "https://www.grid.ac/institutes/grid.412920.c",
"name": [
"City Hospital, Nottingham, UK."
],
"type": "Organization"
},
"familyName": "Dixon",
"givenName": "A R",
"id": "sg:person.01127263010.17",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127263010.17"
],
"type": "Person"
},
{
"familyName": "Jackson",
"givenName": "L",
"id": "sg:person.01362576661.68",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362576661.68"
],
"type": "Person"
},
{
"familyName": "Chan",
"givenName": "S",
"id": "sg:person.010333513372.78",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010333513372.78"
],
"type": "Person"
},
{
"familyName": "Haybittle",
"givenName": "J",
"id": "sg:person.063512001.95",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.063512001.95"
],
"type": "Person"
},
{
"familyName": "Blamey",
"givenName": "R W",
"id": "sg:person.015650304144.58",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015650304144.58"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/bf00174161",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000315787",
"https://doi.org/10.1007/bf00174161"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00000421-198910000-00006",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003943693"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00000421-198910000-00006",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003943693"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00000421-198910000-00006",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003943693"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1111/j.1445-2197.1984.tb06679.x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004642141"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0277-5379(89)90259-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007284388"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/1097-0142(19820201)49:3<413::aid-cncr2820490303>3.0.co;2-s",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008868897"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011360956"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0010-468x(72)90019-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017943682"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0010-468x(72)90019-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017943682"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0277-5379(86)90012-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026924483"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/bjs.1800730925",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027544360"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0140-6736(90)90277-c",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045705046"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0140-6736(90)90277-c",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045705046"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(80)91066-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051618347"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1079527123",
"type": "CreativeWork"
}
],
"datePublished": "1992-08",
"datePublishedReg": "1992-08-01",
"description": "Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m-2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in all sites, including visceral metastases and receptor negative patients. There were no significant differences between treatment groups in the median time (5 months each) to disease progression response duration or survival (13 months megesterol, 11 months mitozantrone) from commencing second-line therapy. Toxicity was considerably higher in the mitozantrone group. Second-line hormonal therapies can produce similar therapeutic results as those achieved from a short course of a 'short option' single agent cytotoxic in patients who were previously thought hormone insensitive. Provided that the patient does not have life threatening disease a trial of megesterol acetate is worth consideration in that it does not prejudice subsequent response to combination cytotoxic chemotherapy.",
"genre": "research_article",
"id": "sg:pub.10.1038/bjc.1992.277",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1017082",
"issn": [
"0007-0920",
"1532-1827"
],
"name": "British Journal of Cancer",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "66"
}
],
"name": "A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer",
"pagination": "bjc1992277",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"949a4cb19ef51988f7ace6dd79494a64cf302393c12ca53303a35bc6d2c5e60b"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"1503915"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"0370635"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/bjc.1992.277"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1031193368"
]
}
],
"sameAs": [
"https://doi.org/10.1038/bjc.1992.277",
"https://app.dimensions.ai/details/publication/pub.1031193368"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T12:15",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000361_0000000361/records_54011_00000000.jsonl",
"type": "ScholarlyArticle",
"url": "http://www.nature.com/articles/bjc1992277"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1992.277'
This table displays all metadata directly associated to this object as RDF triples.
185 TRIPLES
21 PREDICATES
55 URIs
35 LITERALS
23 BLANK NODES